Applications of CREG in treatment of nonalcoholic fatty liver disease and type 2 diabetes

A type 2 diabetes and fatty liver technology, applied in the field of CREG preparations, can solve the problems of gene regulation and therapeutic preparations for untreated diabetes, and achieve the effect of improving fatty liver

Active Publication Date: 2018-07-10
GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is currently no gene regulation and therapeutic agent for the treatment of diabetes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of CREG in treatment of nonalcoholic fatty liver disease and type 2 diabetes
  • Applications of CREG in treatment of nonalcoholic fatty liver disease and type 2 diabetes
  • Applications of CREG in treatment of nonalcoholic fatty liver disease and type 2 diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Embodiment 1. mouse fatty liver, type 2 diabetes model (diet induced obesity, DIO) preparation

[0069](1) Grouping of animals: 8-week-old male WT mice and CREG-KO (or CREG-TG) mice obtained by the aforementioned method were selected and given two special feeds, D12942 high fat diet (High fat diet, HFD) and D12450B Normal chow (NC) feeding, that is, WT-NC group, KO-NC group, WT-HFD group, KO-HFD group, a total of 4 groups (or WT-NC group, TG-NC group, WT-HFD group group, TG-HFD group).

[0070] (2) Operation procedure for the preparation of DIO mice:

[0071] Phenotype correlation analysis was performed on WT and KO (TG) mice to clarify the role of CREG gene on fatty liver and type 2 diabetes. Eight-week-old, male, WT mice and CREG-KO (TG) mice were selected and fed with two special diets, D12942 high-fat diet (Highfat diet, HFD) and D12450B low-fat diet (Normal chow, NC), respectively, namely There are 4 groups including WT-NC group, KO / TG-NC group, WT / TG-HFD group ...

Embodiment 2

[0072] Embodiment 2. Determination of mouse body weight and blood sugar level

[0073] (1) Detection of fasting body weight and feed amount of mice

[0074] ①Fasting: fast the mice to be tested at 8:00 am (without water), and start the experimental operation at 2:00 pm.

[0075] ② Weighing: Weigh at the 0th week, 4th week, 8th week, and 12th week respectively, put a small plastic bucket on the dynamic electronic balance, grab the mouse, put it into the weighing bucket, measure the body weight and record the data .

[0076] ③ Feed amount detection: After the weighing operation is completed, add feed to the mice, and record the amount of feed for the mice on the dynamic electronic balance.

[0077] (2) Detection of fasting blood glucose level in mice

[0078] All the mice to be tested were fasted from 8:00 am to 2:00 pm (without water), that is, the experimental operation was started after 6 hours of fasting.

[0079] ① Blood glucose meter preparation: Check the battery of t...

Embodiment 3

[0084] Example 3. Mouse glucose tolerance test (intraperitoneal glucose tolerance test, IPGTT)

[0085] In the twelfth week of the experiment, the intraperitoneal injection of glucose test (IPGTT) was performed to evaluate the ability of the mice to tolerate glucose.

[0086] (1) Before measuring blood glucose, measure the fasting body weight of the mice, and calculate the injection volume of glucose based on 10 μL / g.

[0087] (2) First detect the fasting blood glucose at 0 minutes before the glucose injection, and inject the glucose solution intraperitoneally quickly after the detection is completed.

[0088] (3) Operation method of intraperitoneal injection

[0089] ①Fix the mouse; hold the mouse, the little finger and ring finger of the left hand grasp the mouse's tail, and the other three fingers grasp the mouse's neck, so that the mouse's head is down and the mouse's abdomen is fully exposed.

[0090] ②Needle positioning and injection: insert the needle from the side of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to uses of a cellular-repressor-of-E1A-stimulated-gene (CREG) protein, particularly to uses of a CREG protein or an active fragment thereof in preparation of drugs for prevention and / or treatment of fatty liver and type 2 diabetes. The present invention further relates to uses of a recombinant vector or recombinant cell expressing a CREG protein or an active fragmentthereof in preparation of drugs for prevention and / or treatment of fatty liver and type 2 diabetes. The invention further relates to related kits, such as kits for predicting fatty liver and type 2 diabetes and / or evaluating treatment effect and prognosis.

Description

technical field [0001] The present invention belongs to the medical use of CREG gene, especially relates to the application of E1A gene activation repressor (Cellularrepressor of E1A-stimulated genes, CREG) in the treatment of non-alcoholic fatty liver disease and type 2 diabetes, and specifically relates to the preparation of CREG preparations to prevent , application in related drugs for relieving and / or treating fatty liver (especially non-alcoholic fatty liver disease) and / or type 2 diabetes. Background technique [0002] Fatty liver, as a pathological metabolic state of the liver, refers to the lesion of excessive accumulation of fat in liver cells caused by various reasons. Fatty liver is generally induced by a variety of diseases, and it is a comprehensive manifestation of the adverse effects of many liver diseases on liver cells. Mild clinical manifestations are asymptomatic, while moderate and severe cases can be life-threatening. According to whether there is a h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61K48/00A61K45/00A61P3/10A61P1/16G01N33/68
CPCA61K38/1709A61K45/00A61K48/005G01N33/68A01K67/0276A01K2217/075A01K2227/105A01K2267/0362A61K38/17A61P3/10A61P1/16A01K2207/15A01K2217/05A01K2217/07C12N15/85
Inventor 韩雅玲张权宇闫承慧田孝祥
Owner GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap